Nation Thailand
BDMS to take majority stake in GNPT to advance Thai cancer therapies
Compiled by KHAO Editorial — aggregated from 1 outlet. See llms.txt for citation guidance.
◌ Single Source
Bangkok Dusit Medical Services (BDMS) plans to invest a further THB170 million in Thai biotechnology company Genepeutic Bio (GNPT), increasing its stake from 19.9% to 55% as it expands into domestically developed cancer cell therapies.
Key facts
- Ruangroj warns of ‘AI theatre’ citing AI investment at 1.7% of revenue in 2026
- Ittiporn told reporters that imported CAR-T medicines used for treatment overseas could cost THB15 million to THB20 million per case for the medicine alone, excluding travel and other hospital expenses
- Foreign patients account for about 30% of BDMS's patient base, with many coming from countries in the Association of Southeast Asian Nations (ASEAN), the Arab world and South Asia, according to the executives.
- The facility could increase that capacity to around 200 patients annually with additional equipment, while the THB170 million investment will also support research and production of other cell therapies.
- Thailand approves THB58.9bn rice support and production reform plan
- GNPT, established in 2020 to turn research from the Faculty of Medicine Ramathibodi Hospital at Mahidol University into medical products, operates a Good Manufacturing Practice (GMP)-certified facility at Thailand Science Park in Pathum
Summary
Health & Wellness
The investment, made through Royal Bangkok Healthcare, a BDMS group company, will give the private hospital operator a majority holding in GNPT. The funding is intended to support further product development, expand manufacturing capacity and advance other treatments, rather than being devoted solely to an existing cancer medicine.